Study on Neurologic and Cognitive Dysfunction in Breast Cancer Patients Undergoing Chemotherapy with Resting State fMRI

2020 ◽  
Author(s):  
Fenshan Zheng ◽  
Peiying Cao ◽  
Jie Zhou ◽  
Chunyu Li ◽  
John Norris
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cognitive Dysfunction ◽  
Resting State ◽  
Resting State Fmri ◽  
Breast Cancer Patients

scholarly journals Network-level functional connectivity alterations in chemotherapy treated breast cancer patients: a longitudinal resting state functional MRI study

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Yun Feng ◽  
Yun Fei Wang ◽  
Li Juan Zheng ◽  
Zhao Shi ◽  
Wei Huang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Functional Connectivity ◽  
Cancer Patients ◽  
Resting State ◽  
Cognitive Assessment ◽  
Breast Cancer Patients ◽  
Assessment Scores ◽  
Blood Biochemical ◽  
Treated Breast ◽  
Treated Breast Cancer

Abstract Background Previous studies have found abnormal structural and functional brain alterations in breast cancer survivors undergoing chemotherapy. However, the network-level brain changes following chemotherapy remain unknown. The purpose of this study was to investigate the dynamic changes of large-scale within- and between-network functional connectivity in chemotherapy-treated breast cancer patients. Methods Seventeen breast cancer patients were evaluated with resting state functional MRI (rs-fMRI), neuropsychological tests and blood examination before postoperative chemotherapy (t0), one week after completing chemotherapy (t1) and six months after completing chemotherapy (t2). Nineteen age- and education level-matched healthy controls (HC) were also recruited. Independent components analysis (ICA) was performed to assess network component using rs-fMRI data. The functional network changes were then correlated with cognitive assessment scores and blood biochemical indexes. Results One-way repeated measures ANOVA revealed significantly changed within-network functional connectivity in the anterior and posterior default mode network (ADMN and PDMN), left and right frontoparietal network (LFPN and RFPN), visual network and self-referential network. Post-hoc test showed that decreased within-network functional connectivity in ADMN, PDMN, LFPN, RFPN, SRN and central network one week after chemotherapy and increased six months after chemotherapy (all P < 0.05). As for the between-network functional connectivity, the PDMN- sensorimotor network connectivity showed the same tendency. Most of these within- and between-network functional connectivity changes were negatively associated with blood biochemical indexes and cognitive assessment scores (all P < 0.05). Conclusions These results indicated that chemotherapy may induce widespread abnormalities in resting state networks, which may serve as a potential biomarker of chemotherapy related cognitive impairment, providing insights for further functional recovery treatment.

Prevalence of self-reported cognitive dysfunction in breast cancer patients.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 131-131
Author(s):  
Heidi Skirbe ◽  
Gabriela Hohn ◽  
Paula Klein ◽  
Mary Ann Juliano ◽  
Jeremy Winell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cognitive Dysfunction ◽  
Medical Center ◽  
Academic Medical Center ◽  
Breast Cancer Patients ◽  
Cognitive Changes ◽  
Convenience Sample ◽  
Cognitive Difficulties ◽  
Emotional Dysfunction

131 Background: In 2011 a series of four time-limited, psycho-educational workshops was conducted by a neuropsychologist at a major urban academic medical center, providing information, coping strategies, and resources to women who had been treated for breast cancer (BrCa) and who then sought cognitive treatment. Based on positive evaluations of these workshops, we assessed the prevalence of self-reported cognitive dysfunction in BrCa patients with the goal of expanding cognitive services to all affected cancer patients. Methods: The study was IRB approved. We surveyed a convenience sample of 50 BrCa patients in a single medical oncology waiting room over several weeks. Subjects completed a 16 item questionnaire assessing potential cognitive problems on a 4 point-scale. Results: Fifty patients completed the survey, of whom 46% were currently employed. Sixty-eight percent of respondents were currently receiving cancer treatment and of those, 61.8% had also received prior treatment. Conclusions: An unexpectedly large proportion of BrCa patients perceived cognitive difficulties that may have been compounded by fatigue and emotional dysfunction. Others may have failed to report cognitive difficulties, unaware of their onset. Quality of life of cancer patients is diminished by cognitive decline. The current data indicate a need for formal assessment and intervention programs that will identify patients with cognitive and emotional dysfunction and remediate the difficulties via workshops and therapy. Formal neuropsychological assessment and treatment resourcestargeting cognitive changes associated with cancer should be expanded to meet documented need. Further research will optimize the scheduling and structure of therapeutic interventions. [Table: see text]

scholarly journals Chemotherapy and Post-traumatic Stress in the Causation of Cognitive Dysfunction in Breast Cancer Patients

2017 ◽  
Vol 109 (10) ◽  
Author(s):  
Kerstin Hermelink ◽  
Markus Bühner ◽  
Philipp Sckopke ◽  
Franziska Neufeld ◽  
Judith Kaste ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cognitive Dysfunction ◽  
Traumatic Stress ◽  
Breast Cancer Patients ◽  
Post Traumatic Stress ◽  
Post Traumatic

Cognitive dysfunction (chemobrain) in breast cancer patients receiving adjuvant therapy: A meta-analysis.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. e19608-e19608
Author(s):  
A. T. Lera ◽  
A. B. Fede ◽  
M. C. Miranda ◽  
A. Ueda ◽  
T. Lerner ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Cognitive Dysfunction ◽  
Meta Analysis ◽  
Breast Cancer Patients

NeuroCog-FX study: A multicenter cohort study on cognitive dysfunction in patients with early breast cancer.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 10061-10061 ◽  
Author(s):  
Oliver Rick ◽  
Monika Reuß-Borst ◽  
Timm Dauelsberg ◽  
Holger Hass ◽  
Volker König ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Risk Factors ◽  
Cognitive Function ◽  
Cancer Patients ◽  
Cognitive Dysfunction ◽  
Clinical Parameters ◽  
Breast Cancer Patients ◽  
Oncological Rehabilitation

10061 Background: Many breast cancer patients complain about cognitive dysfunction (CD) with mnestic and attentional deficits. These complaints persist even after completion of therapy in approximately one third of the patients and affects both social life and working capacity. The exact nature and genesis of CD in breast cancer patients is still not fully understood and risk factors are not yet described. Methods: To determine CD and risk factors, we used the computer-based neuropsychological test NeuroCog-FX during a three weeks oncological rehabilitation in breast cancer patients. Eight subtests addressed attention, working memory, verbal and figural memory, and language. Test duration was < 30 minutes. A cognitive deficit was diagnosed if at least one subtest was clearly below average (score < M - 1.5 SD) of the normative age group. The data on cognitive function were correlated with the level of depression (PHQ-9 test), QoL (EORTC QLQ-30) and clinical parameters (nodal status, chemo-/radiotherapy and endocrine therapy). Results: From February 2013 to December 2014 a total of 476 patients were recruited in 9 oncological rehabilitation centers in Germany. NeuroCog-FX was used to examine 439 patients. Median age was 50 years (range: 24-62 years); 93% of patients had early tumor stage (T0-T2) and 67% were node-negative. Sixty-one percent of the patients received chemotherapy while 84% of the subjects underwent radiotherapy. CD was found in 59% and a moderate to severe depression in 38% of the patients. The severity of depression was correlated with slower reaction times and reduced verbal memory performance. These two cognitive parameters were also associated with a reduced global health status and a reduced physical function score on the EORTC-QLQ30 questionnaire suggesting an impact of cognitive deficits on quality of life. Cognitive function was not associated with type of treatment or node status. Conclusions: In this large and homogeneous cohort of breast cancer patients, CD has been shown in most of the subjects using a valid test method. CD was associated with depression and reduced quality of life. Neither tumor therapy nor other clinical parameters had a significant impact on development of CD.

Sign in / Sign up

Export Citation Format

Share Document